Inovio Pharmaceuticals Inc vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $0.98 (market cap $101.95M), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.61B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 104.1× Inovio Pharmaceuticals Inc's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| INO | RDY | |
|---|---|---|
Market Cap | $101.95M | $10.61B |
Volume | 2,985,847 | 3,738,869 |
Sector | Health | Health |
52-Week High | $2.60 | $15.38 |
52-Week Low | $0.66 | $11.38 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $73.28M | $10.51B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 but has beaten EPS estimates for three consecutive quarters. Key focus remains on the FDA's October 30, 2026 PDUFA decision for INO-3107, its lead candidate for recurrent respiratory papillomatosis. Analyst consensus is bullish with a $2.75 price target, though financials reveal significant losses with a -130,000% net income margin and negative cash flow from operations.
The investment case hinges on regulatory approval of INO-3107, offering substantial upside if successful. However, high cash burn, persistent losses, and dependence on financing pose severe risks. With 59% of analysts rating Buy, the stock presents a high-risk, high-reward opportunity suitable only for speculative investors comfortable with binary outcomes.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →